Donald J Chisholm
Overview
Explore the profile of Donald J Chisholm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bishay R, Tonks K, George J, Samocha-Bonet D, Meyerowitz-Katz G, Chisholm D, et al.
J Clin Endocrinol Metab
. 2020 Dec;
106(3):e1131-e1139.
PMID: 33347566
Context: The etiological mechanism of bile acid (BA) effects on insulin resistance and obesity is unknown. Objective: This work aimed to determine whether plasma BAs are elevated in human obesity...
2.
Tang A, Coster A, Tonks K, Heilbronn L, Pocock N, Purtell L, et al.
J Clin Med
. 2019 May;
8(5).
PMID: 31071971
Background: Large cohort longitudinal studies have almost unanimously concluded that metabolic health in obesity is a transient phenomenon, diminishing in older age. We aimed to assess the fate of insulin...
3.
Tonks K, Coster A, Christopher M, Chaudhuri R, Xu A, Gagnon-Bartsch J, et al.
Obesity (Silver Spring)
. 2016 Feb;
24(4):908-16.
PMID: 26916476
Objective: Alterations in lipids in muscle and plasma have been documented in insulin-resistant people with obesity. Whether these lipid alterations are a reflection of insulin resistance or obesity remains unclear....
4.
Ma X, Lee P, Chisholm D, James D
Front Endocrinol (Lausanne)
. 2015 Feb;
6:1.
PMID: 25688231
Adipocyte differentiation and its impact on restriction or expansion of particular adipose tissue depots have physiological and pathophysiological significance in view of the different functions of these depots. Brown or...
5.
Samocha-Bonet D, Chisholm D, Gribble F, Coster A, Carpenter K, Jones G, et al.
PLoS One
. 2014 Nov;
9(11):e113366.
PMID: 25412338
Background And Aims: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type...
6.
Ma X, Yang P, Kaplan W, Lee B, Wu L, Yang J, et al.
Mol Cell Biol
. 2014 Jul;
34(19):3607-17.
PMID: 25047837
While adipogenesis is controlled by a cascade of transcription factors, the global gene expression profiles in the early phase of adipogenesis are not well defined. Using microarray analysis of gene...
7.
8.
Hocking S, Samocha-Bonet D, Milner K, Greenfield J, Chisholm D
Endocr Rev
. 2013 Apr;
34(4):463-500.
PMID: 23550081
Human adiposity has long been associated with insulin resistance and increased cardiovascular risk, and abdominal adiposity is considered particularly adverse. Intra-abdominal fat is associated with insulin resistance, possibly mediated by...
9.
Samocha-Bonet D, Wong O, Synnott E, Piyaratna N, Douglas A, Gribble F, et al.
J Nutr
. 2011 May;
141(7):1233-8.
PMID: 21593352
Impaired glucagon-like peptide (GLP-1) secretion or response may contribute to ineffective insulin release in type 2 diabetes. The conditionally essential amino acid glutamine stimulates GLP-1 secretion in vitro and in...
10.
Hocking S, Wu L, Guilhaus M, Chisholm D, James D
Diabetes
. 2010 Sep;
59(12):3008-16.
PMID: 20841607
Objective: Visceral adipose tissue (VAT) is more closely linked to insulin resistance than subcutaneous adipose tissue (SAT). We conducted a quantitative analysis of the secretomes of VAT and SAT to...